适合辅助噬菌体治疗的人工关节感染患者比例：法国单中心回顾性研究。

Proportion of patients with prosthetic joint infection eligible for adjuvant phage therapy: a French single-centre retrospective study.

机构信息

Department of Infective and Tropical Diseases, Intercommunal Hospital Centre of Villeneuve- Saint-Georges, Villeneuve-Saint-Georges, 94190, France.

Department of Orthopaedic surgery, Intercommunal Hospital Centre of Villeneuve-Saint- Georges, Villeneuve-Saint-Georges, 94190, France.

出版信息

BMC Infect Dis. 2024 Sep 5;24(1):923. doi: 10.1186/s12879-024-09814-y.

DOI:10.1186/s12879-024-09814-y

PMID:39237903

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11378432/

Abstract

BACKGROUND

Bone and joint infections represent a major public health issue due to their increasing prevalence, their functional prognosis and their cost to society. Phage therapy has valuable anti-biofilm properties against prosthetic joint infections (PJI). The aim of this study was to establish the proportion of patients eligible for phage therapy and to assess their clinical outcome judged against all patients presenting with PJI.

METHOD

. Patients admitted for periprosthetic joint infection (PJI) at a French general hospital between 2015 and 2019 were retrospectively included. Eligibility for phage therapy was determined based on French recommendations, with polymicrobial infections serving as exclusion criteria. Patients were categorized into two groups: those eligible and those ineligible for phage therapy. We analyzed their characteristics and outcomes, including severe adverse events, duration of intravenous antibiotic therapy, length of hospitalization, and relapse rates.

RESULTS

. In this study, 96 patients with PJI were considered in multidisciplinary medical meetings. Of these, 44% patients (42/96) were eligible for additional phage therapy. This group of patients had a longer duration of intravenous therapy (17 days vs. 10 days, p = 0.02), more severe adverse events (11 vs. 3, p = 0.08) and had a longer hospital stay (43 days vs. 18 days, p < 0.01).

CONCLUSION

. A large number of patients met eligibility criteria for phage therapy and treatment and follow-up is more complex. A larger epidemiological study would more accurately describe the prognosis of eligible patients.

摘要

背景

由于其发病率不断上升、功能预后以及对社会的成本，骨和关节感染是一个主要的公共卫生问题。噬菌体疗法具有针对人工关节感染（PJI）的有价值的抗生物膜特性。本研究的目的是确定有资格接受噬菌体治疗的患者比例，并根据所有患有 PJI 的患者评估其临床结果。

方法

在法国一家综合医院，回顾性纳入 2015 年至 2019 年期间因假体周围关节感染（PJI）入院的患者。根据法国的建议确定噬菌体治疗的资格，多微生物感染作为排除标准。患者分为两组：有资格接受噬菌体治疗的和无资格接受噬菌体治疗的。我们分析了他们的特征和结果，包括严重不良事件、静脉内抗生素治疗的持续时间、住院时间和复发率。

结果

在这项研究中，在多学科医疗会议上考虑了 96 例 PJI 患者。其中，44%（42/96）的患者有资格接受额外的噬菌体治疗。这组患者的静脉治疗时间更长（17 天 vs. 10 天，p=0.02），更严重的不良事件（11 例 vs. 3 例，p=0.08），住院时间更长（43 天 vs. 18 天，p<0.01）。